Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
https://doi.org/10.17650/1994-4098-2010-0-2-53-58
Abstract
The main goals of the study were to evaluate the efficacy and safety of intravenous topotecan (Hycamtin) used in a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day course of therapy in patients with recurrent ovarian cancer. The study revealed a number of benefits from use of topotecan in patients with this diagnosis.
About the Authors
E. G. Novikova
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
Russian Federation
Russian Federation
I. A. Korneyeva
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
Russian Federation
Russian Federation
E. A. Ronina
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
Russian Federation
Russian Federation
S. A. Shcheltsyna
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
Russian Federation
Russian Federation
E. D. Pashanov
Medical Department, GlaxoSmithKline, Moscow
Russian Federation
Russian Federation
References
1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, 2010; с. 130–1.
2. Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet 2009;374 (9698):1371–82.
3. Safra T., Menczer J., Bernstein R., Shpigel S. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007;105:205–10.
4. Hoskins W.J., Perez C.A.,Young R.C. Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology. Ozols RF., Rubin S.C., Thomas G. eds. 4th ed. Philadelphia: Lippincott Williams&Wilkins, 2005; p. 919–22.
5. Pujade-Lauraine E., Paraiso D., Cure H. Predicting the effectiveness of chemotherapy (CX) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002;21:abstr 829.
6. Marcman M., Marcman J., Webster K. Duration of response to second- line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120–5.
7. Hertzberg R.P., Caranfa M.J., Hecht S.M. On mechanism of topoisomerase I ingibition by camptotecine: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629–38.
8. Clements M.K., Jones C.B., Cumming M., Daoud S.S. Antiangiogenic potencial of camptotecine and topotecan. Cancer Chemother Pharmacol 1999;44:411–6.
9. Gordon A.N., Fleagle J.T., Guthrie D. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegilated 2 liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312–22.
10. Marcman M., Hall J. Phase II trial of weekly single-agent paclitaxel in platinum paclitaxel-refractory ovarian cancer. J Clin Oncol 2002:20:2365–9.
11. Bence A., Mattingly C. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells. Proc Am Assoc Cancer Res 2002; 43:247; abstr 1227.
Review
For citations:
Novikova E.G., Korneyeva I.A., Ronina E.A., Shcheltsyna S.A., Pashanov E.D. Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life. Tumors of female reproductive system. 2010;(2):53-58. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-2-53-58
Views:
530
Email this article 